Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.38 |
| ▸ | ECE1 | P42892 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 5/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699519 | 0.84 | GLP1R (0.37) | TLR2ECE1TSHRNPSR1RECQL | |
| SCHEMBL3485752 | 0.82 | GLP1R (0.38) | TLR2ECE1TSHRNPSR1GLP1R | |
| SCHEMBL13498598 | 0.82 | GLP1R (0.38) | TLR2ECE1TSHRNPSR1GLP1R | |
| SCHEMBL3485595 | 0.80 | TLR2 (0.33) | TLR2TSHR | |
| SCHEMBL13955336 | 0.80 | TLR2 (0.34) | TLR2 | |
| SCHEMBL13699521 | 0.80 | TSHR (0.36) | TLR2TSHRNPSR1RECQLGLP1R | |
| SCHEMBL24864549 | 0.78 | TLR2 (0.37) | TLR2 | |
| SCHEMBL13699608 | 0.77 | APLNR (0.36) | TLR2 | |
| SCHEMBL13955335 | 0.76 | GLP1R (0.34) | TLR2GLP1R | |
| SCHEMBL13936475 | 0.75 | GLP1R (0.41) | TLR2TSHRRECQLGLP1RFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1853321-A2 | INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1843790-A2 | INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2007-10-17 | — | — | EP | disclosed |
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-07 | — | — | US | disclosed |
| WO-2006087354-A2 | INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| WO-2006079641-A2 | INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-03 | — | — | WO | disclosed |
| EP-1653996-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | Novo Nordisk Health Care AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014035-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | GALE, GALNT2, GALNT1 | TLR2 2632/4885ECE1 1824/4885TSHR 1226/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | TLR2 3322/4885ECE1 1649/4885TSHR 1791/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | TLR2 3322/4885ECE1 1649/4885TSHR 1791/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | TLR2 2632/4885ECE1 1824/4885TSHR 1226/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | TLR2 1081/4885ECE1 380/4885TSHR 323/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | TLR2 2632/4885ECE1 1824/4885TSHR 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.